AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ – an oral therapy for the treatment of patients with hepatitis C

MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment*1 MAVIRET previously received a Notice of Compliance from Health Canada on August 16, 2017 MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease MONTREAL, Feb. 6, 2018 /CNW/ - AbbVie (NYSE: ABBV), a global, research and development-based ...

CDEC Recommends MAVIRET™ and VOSEVI™ for Reimbursement for Chronic HCV

On January 25, 2018 the federal CADTH Canadian Drug Expert Committee (CDEC) released its extensive reviews of two new "pan-genotypic" hepatitis C treatments: Maviret™ (AbbVie) and Vosevi™ (Gilead). In both cases, the drugs were recommended for reimbursement by provincial PharmaCares for "adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis." And, for both, reimburseme...

The Week in Review: July 14 – July 21, 2017

Friday, July 21, 2017 News Recap 1) Vosevi Approved in US – Under Review in Canada Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....

The Week in Review: May 12, 2017 – May 19, 2017

Friday, May 19, 2017 News Recap Canada Help4Hep – BC Helpline Now Online: Did you know that there is now a British Columbia toll-free hepatitis C peer-to-peer helpline where you can get accurate information and meaningful help that is free of charge and confidential?  Check it out now! Help4Hep – BC Helpline Now Online URGENT! Patient and Caregiver Input Request: We Need to Hear your Voice! Patient and Caregiver input is requested by CADTH on Abb...

Patient and Caregiver input is requested by CADTH on AbbVie’s combo of glecaprevir and pibrentasvir (G/P)

URGENT!  Patient and Caregiver Input Request: We Need to Hear your Voice! Patient and Caregiver input is requested by CADTH on AbbVie’s BRAND NEW (not yet for sale in Canada!) combo of glecaprevir and pibrentasvir (G/P) for Genotypes 1-6.  AbbVie’s G/P combo is pan-genotypic (works for all genotypes).  Check out the background information in links below to see the results that have been achieved in clinical trials to date. You will see that the cure rates

Pan-Genotypic Hep C Drug Epclusa™ Recommended for PharmaCare Coverage by CADTH

Epclusa™, a Direct-Acting-Antiviral combo for ALL GENOTYPES of Chronic Hepatitis C, received approval from CADTH on October 28, 2016. This combo of (generics) sofosbuvir and velpatasvir, from Gilead Sciences, was recommended by CADTH's Canadian Drug Expert Committtee (CDEC) for reimbursement by provincial and territorial PharmaCares... "if the following CRITERION and CONDITION are met: (1) CONDITION: "Reduce the price." CDEC noted that the cost of t

Patient Input Is Requested by CADTH on Gilead’s Combo of Sofosbuvir and Velpatasvir for Genotypes 1, 3 and 4

We want to hear your voice! Patient input is requested by CADTH on Gilead’s combo of sofosbuvir and velpatasvir for genotypes 1, 3 and 4.  ANYONE AFFECTED BY HEPATITIS C CAN SUBMIT; it doesn't matter which genotype you are, or if you haven't had any experience with this new treatment. Gilead’s combo is pan-genotypic (works for all genotypes).  Check out the background information below to see the results from clinical trials to date. You will see that the

Canadian Govt. Recommends Treatment for All

New federal guidelines for all genotypes contain great news for doctors and their many patients with chronic hepatitis C (CHC) infection currently denied treatment because they cannot demonstrate liver damage of F2 (fibrosis score) or greater! Comprehensive new hepatitis C treatment guidelines have been released by the national body which recommends health policies for Canada; see https://goo.gl/xvL2HHCADTH (Canadian Agency for Drugs and Technologies in He

Patient Input Requested for Merck Interferon-Free Combo

HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap

View all hepatitis C drug Patient Group input from HepCBC

We are asking for patients to give us input about a new treatment for genotype 4 patients. Are you curious how we use this data?  Want to see what HepCBC tells BC Pharmacare, or the federal drug review agencies about patients' opinions of new hepatitis C treatments? Exactly what did HepCBC tell them about Daklinza (daclatasvir), Holkira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir), Harvoni (sofosbuvir+ledipasvir), Sovaldi (sofusbovir), Sunpr...